

**CURRICULUM VITAE****INFORMAZIONI PERSONALI**

<b>Nome</b>	Sara Galluzzo
<b>Data di nascita</b>	06/01/1975
<b>Qualifica</b>	Dirigente sanitario medico
<b>Amministrazione</b>	AGENZIA ITALIANA DEL FARMACO – AIFA
<b>Incarico attuale</b>	Dirigente medico presso ufficio procedure centralizzate, Settore Innovazione e Strategia del Farmaco
<b>Numero telefonico dell'ufficio</b>	
<b>Fax dell'ufficio</b>	
<b>E-mail istituzionale</b>	s.galluzzo@aifa.gov.it

<b>Titolo di studio</b>	Laurea in Medicina e Chirurgia
<b>Altri titoli di studio e professionali</b>	Diploma di Specializzazione in Medicina Interna, Università la Sapienza, Roma  Dottorato di Ricerca in Oncologia Sperimentale, Università Campus Bio-Medico di Roma e Columbia University New York  Master II livello sperimentazione clinica, affari regolatori, aspetti etici, Università Cattolica, Roma

<p><b>Esperienze professionali (incarichi ricoperti)</b></p>	<p>- Da Aprile 2020 ad oggi Membro dell'Emergency Task Force (ETF) per il COVID-19 dell'Agenzia Europea dei Medicinali (EMA), Amsterdam.</p> <p>- Da marzo 2020 ad oggi Membro Scientific Advice Working Party (nomina PDCO) dell'Agenzia Europea dei Medicinali (EMA), Amsterdam.</p> <p>-Da luglio 2016 ad oggi Membro Italiano presso il Comitato Pediatrico (PDCO) dell'Agenzia Europea dei Medicinali (EMA), Amsterdam.</p> <p>-Da novembre 2010 ad oggi assessor clinico e product team leader di procedure autorizzative centralizzate nell'ambito del CHMP; esperto clinico per procedure di "scientific advices" nazionali, EMA, EMA-HTA; istruttorie CTS e CPR; esperto clinico valutazione sperimentazioni cliniche.</p> <p>-Da Maggio 2006 a novembre 2010 Medico specialista. Titolare di contratto con funzioni di assistente nell'ambito clinico, didattico e di ricerca presso l'UOC di Oncologia Medica dell' Università Campus Bio-Medico di Roma, in particolare ruolo di responsabile del Laboratorio di Oncologia Translazionale e di Coordinatore dell'unità dei trials clinici.</p> <p>-Da Maggio 2005 a maggio 2006 Medico specialista, dottorando. Titolare di contratto con funzioni di assistente nell'ambito clinico, didattico e di ricerca presso l'Unità di Immunologia Clinica Università Campus Bio-Medico di Roma.</p> <p>-2007-2011 docente incaricato di Immunologia nel Corso di Laurea in Medicina e Chirurgia e della scuola di specializzazione in Oncologia Medica, Università Campus Bio-Medico di Roma;</p> <p>-2008-2011 docente incaricato di Patologia Generale (Corso di Tecnici di Radiologia e Radioterapia e Corso di Dietistica e Nutrizione), Università Campus Bio Medico di Roma.</p>
<p><b>Capacità linguistiche</b></p>	<p>Inglese C1</p>
<p><b>Capacità nell'uso delle tecnologie</b></p>	<p>Utente avanzato delle principali tecnologie informatiche.</p>
<p><b>Altro (partecipazione a convegni e seminari, pubblicazioni, collaborazione a riviste, ecc., ed ogni altra informazione che il dirigente ritiene di dover pubblicare)</b></p>	<p>Co-autore di 47 lavori pubblicati su riviste internazionali con IF</p> <p>Karres D, Lesa G, Ligas F, Annunen P, Van Dartel M, Demolis P, Galluzzo S, Herold R, Kholmanskikh van Crieckingen O, Stoyanova-Beninska V, Koen Norga K.</p> <p>Can a Multistakeholder Prioritization Structure Support Regulatory Decision Making? A Review of Pediatric Oncology Strategy Forums Reflecting on Challenges and Opportunities of this Concept Clin Pharmacol Ther. 2020 Sep;108(3):553-556</p> <p>- Pearson ADJ, Rossig C, Lesa G, Diede SJ, Weiner S, Anderson J, Gray J, Geoerger B, Minard-Colin V, Marshall LV, Smith M, Sondel P, Bajars M, Baldazzi C, Barry E, Blackman S, Blanc P, Capdeville R, Caron H, Cole PD, Jiménez JC, Demolis P, Donoghue M, Elgadi M, Gajewski T, Galluzzo S, et al.</p>

ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. *Eur J Cancer*. 2020 Mar;127:52-66

-Luciani F, Galluzzo S (Co-first author), Gaggioli A, Aaby Kruse N, Venneugues P, Schneider CK, Pini C, Melchiorri D. Implementing quality by design for biotech products: are regulators on track? *MAbs*. 2015;7(3):451-5;

-Boix-Perales H, Borregaard J, Jensen KB, Ersbøll J, Galluzzo S, Giuliani R, Ciceroni C, Melchiorri D, Salmonson T, Bergh J, Schellens JH, Pignatti F. The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. *Oncologist*. 2014 Jul;19(7):766-73

-Angeletti S, Gherardi G, De Florio L, Avola A, Crea F, Riva E, Vitali MA, Galluzzo S, Dicuonzo G. Real-time polymerase chain reaction with melting analysis of positive blood culture specimens in bloodstream infections: diagnostic value and turnaround time. *New Microbiol*. 2013 Jan;36(1):65-74.

-Galluzzo S, Patti G, Dicuonzo G, Di Sciascio G, Tonini G, Ferraro E, Spoto C, Campanale R and Angeletti S. Association between NOD2/CARD15 polymorphisms and coronary artery disease: a prospective, case-control study. *Hum Immunol*. 2011 Aug;72(8):636-40.

-D Santini, B Vincenzi, V Adamo, R Addeo, V Fusco A Russo, F Montemurro, I Roato, S Redana, G Lanzetta, MA Satolli, A Berruti, V Leoni, Galluzzo S, M Antimi, G Ferraro, M Rossi, S Del Prete, MR Valerio, M Caraglia and G Tonini. Cigarettes smoking habit does not reduce benefit from first line trastuzumab-based treatment in advanced breast cancer patients. *Oncol Rep*. 2011 Mar 28.

-B Vincenzi, G Perrone, S Galluzzo, A Frezza, D Santini, A Zoccoli, G Tonini. PML As A Potential Predictive Factor Of Efficacy Of Oxaliplatin Based First Line Chemotherapy In Colorectal Cancer Patients. *J Cell Physiol*. 2011 Apr 18.

-Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, La Verde N, Caroti C, Treilleux I, Ruggiero A, Perrone G, Addeo R, Clezardin P, Onetti Muda A, Tonini G. Receptor activator of NF- $\kappa$ B (RANK) expression associates with bone metastasis occurrence in breast cancer patients. *PLoS One*. 2011 Apr 29;6(4):e19234.

-Santini D, Galluzzo S, Gaeta L, Zoccoli A, Riva E, Ruzzo A, Vincenzi B, Graziano F, Loupakis F, Falcone A, Muda AO, Tonini G. Should Oncologists Be Aware in Their Clinical Practice of KRAS Molecular Analysis? *J Clin Oncol*. 2011 Jan 24.

-Fratto ME, Santini D, Vincenzi B, Silvestris N, Azzariti A, Tommasi S, Zoccoli A, Galluzzo S, Maiello E, Colucci G, Tonini G. Targeting EGFR in bilio-pancreatic and liver carcinoma. *Front Biosci (Schol Ed)*. 2011 Jan 1;3:16-22.

-Santini D, Fratto ME, Spoto C, Galluzzo S, Zoccoli A, Vincenzi B, Tonini G. Cetuximab in small bowel adenocarcinoma (SBA): a new friend? *Br J Cancer*. 2010 Oct 12; 103 (8):1305

-Santini D, Galluzzo S, Zoccoli A, Pantano F, Fratto ME, Vincenzi B, Lombardi L, Gucciardino C,

Silvestris N, Riva E, Rizzo S, Russo A, Maiello E, Colucci G, Tonini G. New molecular targets in bone metastases. *Cancer Treat Rev.* 2010 Nov;36 Suppl 3:S6-S10.

-Galluzzo S, Vincenzi B, Santini D, Rocci L, Loupakis F, P Correale, R Addeo, A Zoccoli, A Napolitano, F Graziano, A Ruzzo, S Del Prete, A Falcone, G Francini, G Dicuonzo and G Tonini. Early magnesium modifications as a surrogate markers of efficacy of cetuximab based anticancer treatment in advanced colorectal cancer patients KRAS wild-type. *Annals of Oncology,* 2010, Nov, 29

-B Vincenzi, A Zoccoli, F Pantano, O Venditti, S Galluzzo. Cetuximab: FROM BENCH TO BEDSIDE. *Curr Cancer Drug Targets.* 2010 Feb 1;10(1):80-95. Review.

-Santini D, Fratto ME, Vincenzi B, Napoli N, Galluzzo S, Tantardini M, Abbruzzese A, Caraglia M, Tonini G. Denosumab: the era of targeted therapies in bone metastatic diseases. *Curr Cancer Drug Targets.* 2009 Nov;9(7):834-42. Review.

-Galluzzo S, Santini D, Vincenzi B, Zoccoli A, Ferraro E, Lippi C., Altomare V., Tonini G., Bertoldo F. Longitudinal evaluation of vitamin D plasma levels during anthracycline and docetaxel-based adjuvant chemotherapy in early breast cancer patients. *Ann Oncol.* 2010 Jan;21(1):185-6.

-S Angeletti, S Galluzzo, D Santini, A Ruzzo, B Vincenzi, E Ferraro, C Spoto, G Lorino, N M Graziano, M Magnani, F Graziano, G Tonini and G Dicuonzo. NOD2 polymorphisms impair innate immunity and increase the susceptibility to gastric cancer in Italian population. *Hum Immunol.* 2009 Sep;70(9):729-32.

-Pantano F, Silletta M, Iovieno A, Vincenzi B, Santini D, Galluzzo S, Bonini S, Tonini G. Stevens-Johnson syndrome associated with reduced tear production complicating the use of cetuximab and panitumumab. *Int J Colorectal Dis.* 2009 Feb 19

-Vincenzi B, Patti G, Galluzzo S, Pantano F, Venditti O, Santini D, Ruzzo A, Schiavon G, Caraglia M, Marra M, Graziano F, Tonini G. Interleukin 1beta-511T gene (IL1beta) polymorphism is correlated with gastric cancer in the Caucasian population: results from a meta-analysis. *Oncol Rep.* 2008 Nov;20(5):1213-20.

-Santini D, Angeletti S, Ruzzo A, Dicuonzo G, Galluzzo S, Vincenzi B, Calvieri A, Pizzagalli F, Graziano N, Ferraro E, Lorino G, Altomare A, Magnani M, Graziano F, Tonini G. Toll like receptor 4 (TLR 4) Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotype. *Clin Exp Immunol.* 2008 Dec;154(3):360-4.

-Santini D, Fratto ME, Galluzzo S, Vincenzi B, Tonini G. Are bisphosphonates the suitable anticancer drugs for the elderly? *Crit Rev Oncol Hematol.* 2008 Aug 7.

-Vincenzi B, Santini D, Galluzzo S, Russo A, Fulfarò F, Silletta M, Battistoni F, Rocci L, Zobel BB, Adamo V, Dicuonzo G, Tonini G. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. *Clin Cancer Res.* 2008 Jul 1;14(13):4219-24.

-Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, Agrati C, Turchi F, Piacentini P, Rocci L,

Manavalan JS, Tonini G, Poccia F. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. *Cancer Immunol Immunother.* 2008 May 6

-Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, Schiavon G, Angeletti S, Uzzalli F, Caraglia M, Dicuonzo G and Tonini G. Repeated intermittent low-dose therapy with ZA induces an early, sustained and long-lasting decrease of peripheral vessel endothelial growth factor (VEGF) levels in cancer patients. *Clin Cancer Res.* 2007 Aug 1;13(15 Pt 1):4482-6.

-S. Galluzzo, D. Santini, B. Vincenzi, N. Caccamo, S. Meraviglia, A. Salerno, F. Dieli and G. Tonini Immunomodulating role of bisphosphonates on human gamma delta T cells-: an intriguing and promising aspect of their antitumor activity. *Expert Opin Ther Targets.* 2007 Jul;11(7):941-54. Review.

-Santini D., Galluzzo S., Vincenzi B., Schiavon G., Fratto E., Pantano F. and Tonini G. New developments of aminobisphosphonates: the double face of Janus. *Annals of Oncology* 2007, 18 (S6), 164-167.

-Suciu-Foca N., Feirt N, Zhang Q-Y, Vlad G, Liu Z, Lin H, Chang C-C, Ho E, Colovai A, Kaufman H, D'Agati V, Thaker HM, Remotti H, Galluzzo S, Cinti P, Rabitti C, Allendorf J, Chabot J, Caricato M, Coppola R, Berloco P, Cortesini R. Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. *Journal of Immunology,* 2007 Jun 1;178(11):7432-41

-Santini D, Fratto ME, Vincenzi B, Galluzzo S, Tonini G. Zoledronic acid in the management of metastatic bone disease. *Expert Opin Biol Ther.* 2006 Dec;6(12):1333-48.

-Amoroso A., Cacciapaglia F., De Castro S., Battagliese A., Coppolino G., Galluzzo S., Vadacca M., Afeltra A. The adjunctive role of antiphospholipid antibodies in systemic lupus erythematosus cardiac involvement *Clinical and Experimental Rheumatology,* May-Jun 24(3), 287-94.

-Bruni R., Serino FM, Galluzzo S, Coppolino G, Vadacca M, Nilo S, Terminio N, Afeltra A. Alexithymia and Neurendocrine Immune response in patients with autoimmune diseases: preliminary results on relationship between alexithymic construct and TNF-alfa levels. *Annals of New York Academy of Sciences* 2006 Jun;1069:208-11.

-Afeltra A, Vadacca M, Conti L, Galluzzo S, Mitterhofer AP, Ferri GM, Del Porto F, Caccavo D, Gandolfo GM, Amoroso A. Thrombosis in systemic lupus erythematosus: congenital and acquired risk factors. *Arthritis Rheum.* 2005 Jun 15;53(3):452-9.

-Caccavo D, Rigon A, Picardi A, Galluzzo S, Vadacca M, Ferri GM, Amoroso A, Afeltra A. Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates. *Clin Rheumatol.* 2005 Aug;24(4):381-7. Epub 2004 Dec 9.

-Suciu-Foca N, Manavalan JS, Scotto L, Kim-Schulze S, Galluzzo S, Naiyer AJ, Fan J, Vlad G, Cortesini R. Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: review. *Int Immunopharmacol.* 2005 Jan;5(1):7-11. Review.

-Scotto L, Naiyer AJ, Galluzzo S, Rossi P, Manavalan JS, Kim-Schulze S, Fang J, Favera RD, Cortesini R, Suciu-Foca N. Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28- T suppressor cells. *Hum Immunol.* 2004 Nov;65(11):1297-306.

-Cortesini NS, Colovai AI, Manavalan JS, Galluzzo S, Naiyer AJ, Liu J, Vlad G, Kim-Schulze S, Scotto L, Fan J, Cortesini R. Role of regulatory and suppressor T-cells in the induction of ILT3+ ILT4+ tolerogenic endothelial cells in organ allografts. *Transpl Immunol.* 2004 Sep-Oct;13(2):73-82. Review

-Amoroso A, Gigante A, Gianni C, Amoroso D, Zennaro D, Galluzzo S, Caccavo D. Safety of conventional drugs and biologic agents for Rheumatoid Arthritis. *Eur Rev Med Pharmacol Sci.* 2003 Sep-Oct;7(5):139-45. Review.

-Caccavo D, Del Porto F, Garzia P, Mitterhofer AP, Galluzzo S, Rigon A, Vadacca M, Navajas MF, Amoroso A, Afeltra A. Raynaud's phenomenon and antiphospholipid antibodies in systemic lupus erythematosus: is there an association? *Ann Rheum Dis.* 2003 Oct;62(10):1003-5.

-Afeltra A, Garzia P, Mitterhofer AP, Vadacca M, Galluzzo S, Del Porto F, Finamore L, Pascucci S, Gasparini M, Lagana B, Caccavo D, Ferri GM, Amoroso A, Francia A. Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. *Neurology.* 2003 Jul 8;61(1):108-10.

-Caccavo D, Garzia P, Sebastiani GD, Ferri GM, Galluzzo S, Vadacca M, Rigon A, Afeltra A, Amoroso A. Expression of lactoferrin on neutrophil granulocytes from synovial fluid and peripheral blood of patients with rheumatoid arthritis. *J Rheumatol.* 2003 Feb;30(2):220-4.

-Amoroso A, Mitterhofer AP, Del Porto F, Garzia P, Ferri GM, Galluzzo S, Vadacca M, Caccavo D, Afeltra A. Antibodies to anionic phospholipids and anti-beta2-GPI: association with thrombosis and thrombocytopenia in systemic lupus erythematosus. *Hum Immunol.* 2003 Feb;64(2):265-73.

-Amoroso A, Garzia P, Vadacca M, Galluzzo S, Del Porto F, Mitterhofer AP, Afeltra A. The unusual association of three autoimmune diseases in a patient with Noonan syndrome. *J Adolesc Health.* 2003 Jan;32(1):94-7.

-Afeltra A, Amoroso A, Mitterhofer AP, Vadacca M, Galluzzo S, Francia A, Del Porto F, Gandolfo GM. The 677C --> T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene in epileptic patients affected by systemic lupus erythematosus. *Seizure.* 2002 Jun;11(4):250-4.

-Spoto S, Galluzzo S, De Galasso L, Zobel B, Navajas MF. Prevention of acute tubular necrosis caused by the administration of non-ionic radiologic contrast media. *Clin Ter.* 2000 Sep-Oct;151(5):323-7.

-Picardi A, Manfrini S, Navajas F, Zardi E, Amicarelli E, De Iorio F, Galluzzo S, Valiani A, Spoto S, Scarlata S, Vespasiani Gentilucci U, De Galasso L, Meloni MC, Costantino S. 67 year old man with abdominal pain, anorexia and low-grade fever. *Clin Ter.* 2000 Jul-Aug;151(4):287-91.

-Picardi A, Manfrini S, Navajas F, Amicarelli E, De Iorio F, Valiani A, Galluzzo S, Spoto S, Segna A, Scarlata S, Vespasiani Gentilucci U, De Galasso L, Meloni MC, Costantino S. A 73-year-old woman with vomiting and metabolic alkalosis. *Clin Ter.* 2000 Mar-Apr;151(2):119-23.

-Amoroso A, Mitterhofer AP, Ferri GM, Galluzzo S, Vadacca M, Afeltra A. Neurological involvement in antiphospholipid antibodies syndrome (APS). *Eur Rev Med Pharmacol Sci.* 1999 Sep-Oct;3(5):205-9. Review.

R  
o  
m  
a  
,